Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2012

01-08-2012 | Lung Cancer (T Mekhail, Section Editor)

Thymic Neoplasms: a Clinical Update

Authors: Mark Mikhail, Yasmin Mekhail, Tarek Mekhail

Published in: Current Oncology Reports | Issue 4/2012

Login to get access

Abstract

Thymoma is a unique neoplasm of the anterior mediastinum that is frequently associated with indolent growth and a variety of paraneoplastic syndromes. One third of cases are detected during the evaluation of myasthenia gravis. Classification systems of thymoma have limited ability in accurately predicting prognosis and course of disease. Thus, staging is the only way to predict clinical behavior. Encapsulated tumors that are surgically resected carry the best prognosis. Adjuvant radiotherapy is recommended for incompletely excised and most invasive thymomas. Chemotherapy in anthracycline-based chemotherapy remains the most effective chemotherapy for neoadjuvant, adjuvant or palliative treatment.
Literature
1.
Miller JF. Thymus and immunity–II. The last three decades. Eur J Cancer Clin Oncol. 1988;24(8):1257–62.PubMedCrossRef
2.
Mller-Hermelink HK, Wilisch A, Schultz A, Marx A. Characterization of the human thymic microenvironment: lymphoepithelial interaction in normal thymus and thymoma. Arch Histol Cytol. 1997;60(1):9–28.CrossRef
3.
4.
Thomas CR. Thymoma: State of the art. J Clin Oncol. 1999;17(7):2280.PubMed
5.
6.
Engels EA. Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105(4):546.PubMedCrossRef
7.
Mullen B. Primary anterior mediastinal tumors in children and adults. Ann Thorac Surg. 1986;42:338–45.PubMedCrossRef
8.
Wilkins Jr EW. Role of staging in prognosis and management of thymoma. Ann Thorac Surg. 1991;51(6):888.PubMedCrossRef
9.
Loehrer Sr PJ. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. Cancer. 2001;91(11):2010.PubMedCrossRef
10.
Sperling B. Thymoma: A review of the clinical and pathological findings in 65 cases. Can J Surg. 2003;46(1):37.PubMed
11.
Blumberg D. Thymoma: A multivariate analysis of factors predicting survival. Ann Thorac Surg. 1995;60(4):908.PubMedCrossRef
12.
13.
Wilkins KB. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg. 1999;230(4):562.PubMedCrossRef
14.
Froudarakis ME. Invasive thymoma: A clinical study of 23 cases. Respiration. 2000;68(4):376.CrossRef
15.
Fujimura S. Results of surgical treatment for thymoma based on 66 patients. J Thorac Cardiovasc Surg. 1987;93(5):708.PubMed
16.
Do Y. CT findings in malignant tumors of thymic epithelium. J Comput Assist Tomogr. 1995;19(2):192.PubMedCrossRef
17.
van de Wijngaert FP, Kendall MD, Schuurman HJ, Rademakers LH, Kater L. Heterogeneity of epithelial cells in the human thymus. An ultrastructural study. Cell Tissue Res. 1984;237(2):227–37.PubMedCrossRef
18.
Marino M. Thymoma and thymic carcinoma. Virchows Arch. 1985;407(2):119–49.CrossRef
19.
20.
Rios A. Prognostic factors in thymic epithelial neoplasms. Eur J Cardiothorac Surg. 2002;21(2):307.PubMedCrossRef
21.
Sassa, Mizushima Y, Kusajima Y, Sugiyama S, Noto H, Kobayashi M. Clinical study on thymoma: Assessment of prognostic factors. Anticancer Res. 1996;16(6B):3895–900.
22.
Lardinois D. Prognostic relevance of masaoka and Müller-hermelink classification in patients with thymic tumors. Ann Thorac Surg. 2000;69(5):1550.PubMedCrossRef
23.
Latz D. Invasive thymoma: Treatment with postoperative radiation therapy. Radiology. 1997;204(3):859.PubMed
24.
Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77(4):1183–8. 4.PubMedCrossRef
25.
Mayer R. Radiotherapy for invasive thymoma and thymic carcinoma. Strahlenther Onkol. 1999;175(6):271.PubMedCrossRef
26.
Allen MS. Benign mediastinal germ cell tumors. In: Wood DE, Thomas CR, editors. Mediastinal Tumors: Update 1995. Springer-Verlag; 1995. p. 37–42.
27.
Zhang Z, Ren H, Yu H, Li Z, Liu H, Lu Z. Thymic carcinoid tumor–a report of 7 cases. Chin Med Sci J. 1993;8(1):48–51.PubMed
28.
29.
Asbun HJ, Calabria RP, Calmes S, Lang AG, Bloch JH. Thymic carcinoid. Am Surg. 1991;57(7):442–5.PubMed
30.
Falkson CB. The management of thymoma: A systematic review and practice guideline. J Thorac Oncol. 2009;4(7):911.PubMedCrossRef
31.
32.
33.
34.
Lattes R. Thymoma and other tumors of the thymus. An analysis of 107 cases. Cancer. 1962;15(6):1224.CrossRef
35.
Lewis JE. Thymoma. A clinicopathologic review. Cancer. 1987;60(11):2727.
36.
37.
38.
Masaoka A. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48(11):2485.PubMedCrossRef
39.
Bernatz PE, Harrison EG, Clagett OT. Thymoma: A clinicopathologic study. J Thorac Cardiovasc Surg. 1961;42:424–44.PubMed
40.
Kirchner T, Muller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Pathol. 1989;10:167–89.
41.
Cornea R, Cimpean AM, Raica M. World health organization histo-morphologic classification of thymomas. pros and cons. TMJ. 2009;59(3–4):371–7.
42.
Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81(6):2328.PubMedCrossRef
43.
Verley JM. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. 1985;55(5):1074.PubMedCrossRef
44.
45.
Bernatz P, Khonsari S, Harrison E, Taylor W. Thymoma: Factors influencing prognosis. Surg Clin North Am. 1973;53(4):885–92. 08.PubMed
46.
Levine GD. Thymic hyperplasia and neoplasia: A review of current concepts. Hum Pathol. 1978;9(5):495.PubMedCrossRef
47.
48.
Legg MA. Pathology and clinical behavior of thymomas. A survey of 51 cases. Cancer. 1965;18(9):1131.PubMedCrossRef
49.
Singhal S, Shrager JB, Rosenthal DI, LiVolsi VA, Kaiser LR. Comparison of stages I–II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg. 2003;76(5):1635–42. 11.PubMedCrossRef
50.
Mangi AA, Wright CD, Allan JS, Wain JC, Donahue DM, Grillo HC, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002;74(4):1033–7. 10.PubMedCrossRef
51.
Mangi AA, Wain JC, Donahue DM, Grillo HC, Mathisen DJ, Wright CD. Adjuvant radiation of stage III thymoma: Is it necessary? Ann Thorac Surg. 2005;79(6):1834–9. 6.PubMedCrossRef
52.
53.
Verstandig AG, Epstein DM, Miller WT, Aronchik JA, Gefter WB. Thymoma–report of 71 cases and a review. Crit Rev Diagn Imaging. 1992;33(3):201–30.PubMed
54.
Lewis BD. Benign teratomas of the mediastinum. J Thorac Cardiovasc Surg. 1983;86(5):727.PubMed
55.
Armstrong P. Mediastinal and hilar disorders. In: Armstrong P, Wilson AG, Dee P, Hansell DM, editors. Imaging of Diseases of the Chest. London: Mosby; 2000. p. 789–949.
56.
Regnard JF. Prognostic factors and long-term results after thymoma resection: A series of 307 patients. J Thorac Cardiovasc Surg. 1996;112(2):376.PubMedCrossRef
57.
58.
59.
Wilkins Jr EW. Cases of thymoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg. 1966;52(3):322.PubMed
60.
61.
62.
Gawrychowski J. Thymoma–the usefulness of some prognostic factors for diagnosis and surgical treatment. Eur J Surg Oncol. 2000;26(3):203.PubMedCrossRef
63.
Haniuda M. Recurrence of thymoma: Clinicopathological features, re-operation, and outcome. J Surg Oncol. 2001;78(3):183.PubMedCrossRef
64.
65.
Matsushima S, Yamamoto H, Egami K, Suzuki S, Tanaka S. Evaluation of the prognostic factors after thymoma resection. Int Surg. 2001;86(2):103–6.
66.
Nakahara K. Thymoma: Results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg. 1988;95(6):1041.PubMed
67.
Okumura M. Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg. 1999;117(3):605.PubMedCrossRef
68.
Sakai S. Differential diagnosis between thymoma and non-thymoma by dynamic MR imaging. Acta Radiol. 2002;43(3):262.PubMedCrossRef
69.
70.
Rosado-de-Christenson ML. Thymoma: Radiologic-pathologic correlation. Radiographics. 1992;12(1):151.PubMed
71.
Jeong YJ, Does CT. of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? AJR. Am J Roentgenol. 2004;183(2):283.
72.
73.
Sasaki M. Differential diagnosis of thymic tumors using a combination of 11 C-methionine PET and FDG PET. J Nucl Med. 1999;40(10):1595.PubMed
74.
Liu RS. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report. Eur J Nucl Med. 1995;22(12):1402.PubMedCrossRef
75.
Curran Jr W, Kornstein M, Brooks J, Turrisi A. Invasive thymoma: The role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6(11):1722–7.PubMed
76.
Monden Y, Nakahara K, Iioka S, Nanjo S, Ohno K, Fujii Y, et al. Recurrence of thymoma: Clinicopathological features, therapy, and prognosis. Ann Thorac Surg. 1985;39(2):165–9.PubMedCrossRef
77.
Haniuda M, Morimoto M, Nishimura H, Kobayashi O, Yamanda T, Iida F. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg. 1992;54(2):311–5.PubMedCrossRef
78.
Haniuda M, Miyazawa M, Yoshida K, Oguchi M, Sakai F, Izuno I, et al. Is postoperative radiotherapy for thymoma effective? Ann Surg. 1996;224(2):219.PubMedCrossRef
79.
Fornasiero A, Daniele O, Ghiotto C, Fiorentino MV, Piazza M, Fiore-Donati L, et al. Chemotherapy for invasive thymoma. A 13–year experience. Cancer. 1991;68(1):30–3.PubMedCrossRef
80.
Loehrer Sr PJ, Kim KM, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The eastern cooperative oncology group, southwest oncology group, and southeastern cancer study group. J Clin Oncol. 1994;12(6):1164–8.PubMed
81.
Pj SL, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. J Clin Oncol. 1997;15(9):3093–9.
82.
Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European organization for research and treatment of cancer lung cancer cooperative group. J Clin Oncol. 1996;14(3):814–20.PubMed
83.
Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, P Terrier, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol. 2010;5(6):893.PubMedCrossRef
84.
Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29(15):2060–5.PubMedCrossRef
85.
Ito J, Sekiya M, Miura K, Yoshimi K, Suzuki T, Seyama K, et al. Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone. Intern Med. 2009;48(12):1061–4.PubMedCrossRef
86.
Loehrer Sr PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An eastern cooperative oncology group phase II trial. J Clin Oncol. 2004;22(2):293–9.PubMedCrossRef
87.
Pettit L, El-Modir A. The role of somatostatin analogues in the treatment of advanced malignant thymomas: Case report and review of the literature. Br J Radiol. 2011;84(997):e7–10.PubMedCrossRef
88.
Souadjian JV, Enriquez P, Silverstein MN, Ppin JM. The spectrum of diseases associated with thymoma. coincidence or syndrome? Arch Intern Med. 1974;134(2):374–9.PubMedCrossRef
89.
90.
Maggi G. Thymomas: A review of 169 cases, with particular reference to results of surgical treatment. Cancer. 1986;58(3):765.PubMedCrossRef
91.
92.
93.
Kirchner T. Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol. 1992;16(12):1153.PubMedCrossRef
94.
95.
96.
97.
Wilkins Jr EW. Thymoma: A continuing survey at the Massachusetts General Hospital. Ann Thorac Surg. 1979;28(3):252.PubMedCrossRef
98.
99.
Bergh NP. Tumors of the thymus and thymic region: I. clinicopathological studies on thymomas. Ann Thorac Surg. 1978;25(2):91.PubMedCrossRef
100.
Waldmann TA. Thymoma, hypogammaglobulinemia and absence of eosinophils. J Clin Invest. 1967;46:1127.CrossRef
101.
Kumura J. Post-thymectomy myasthenia gravis: Report a case of ocular myasthenia gravis after total removal of a thymoma and review of the literature. Neurology. 1967;17:413.CrossRef
102.
Wick MR, Rosai J. The endocrine thymus. In: Kovac K, Asa SI, editors. Functional Endocrine Pathology, vol. 2. Boston: Blackwell Scientific; 1991. p. 790–813.
103.
Rosai J, Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. clinicopathologic study of 8 cases. Cancer. 1972;29(4):1061–74.PubMedCrossRef
104.
Wick M, Scott R, Li CY, Carney J. In: Carcinoid tumor of the thymus: A clinicopathologic report of seven cases with a review of the literature. Mayo Clin Proc. 1980;55(4):246–54.
105.
Sugiura H, Morikawa T, Itoh K, Ono K, Okushiba S, Kondo S, et al. Thymic carcinoid in a patient with multiple endocrine neoplasia type 1: Report of a case. Surg Today. 2001;31(5):428–32.PubMedCrossRef
106.
Teh B. Thymic carcinoids in multiple endocrine neoplasia type 1. J Intern Med. 1998;243(6):501–4.PubMedCrossRef
Metadata
Title
Thymic Neoplasms: a Clinical Update
Authors
Mark Mikhail
Yasmin Mekhail
Tarek Mekhail
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 4/2012
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0246-8

Other articles of this Issue 4/2012

Current Oncology Reports 4/2012 Go to the issue

Lung Cancer (T Mekhail, Section Editor)

Current Developments in the Management of Locally Advanced Esophageal Cancer

Lung Cancer (T Mekhail, Section Editor)

Management of Non-Small Cell Lung Cancer with Oligometastasis

Palliative Medicine (A Jatoi, Section Editor)

Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers

Palliative Medicine (A Jatoi, Section Editor)

VEGF Inhibition, Hypertension, and Renal Toxicity

Palliative Medicine (A Jatoi, Section Editor)

Nasal Septal Perforation from Bevacizumab: A Discussion of Outcomes, Management, and Pharmacovigilance

Palliative Medicine (A Jatoi, Section Editor)

The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits